Hepatoblastoma Differential Diagnoses

  • Author: Jennifer R Willert, MD; Chief Editor: Max J Coppes, MD, PhD, MBA   more...
 
Updated: Jan 4, 2010
 
 

Differential Diagnoses

Proceed to Workup
 
 
Contributor Information and Disclosures
Author

Jennifer R Willert, MD  Medical Director, Supportive and Palliative Care, Assistant Clinical Professor of Pediatrics, University of California San Diego; Consulting Staff, Department of Pediatrics, Division of Hematology, Oncology and Blood and Marrow Transplant, Rady Children's Hospital; Member, Rebecca Moore's Cancer Center, Translational Oncology, University of California San Diego Medical Center

Jennifer R Willert, MD is a member of the following medical societies: American Academy of Pediatrics, American Society for Blood and Marrow Transplantation, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Children's Oncology Group

Disclosure: Nothing to disclose.

Coauthor(s)

Gary Dahl, MD  Professor, Department of Pediatrics, Division of Hematology/Oncology, Stanford University School of Medicine

Gary Dahl, MD is a member of the following medical societies: American Society of Hematology and American Society of Pediatric Hematology/Oncology

Disclosure: Nothing to disclose.

Specialty Editor Board

Stephan A Grupp, MD, PhD  Director, Stem Cell Biology Program, Department of Pediatrics, Division of Oncology, Children's Hospital of Philadelphia; Associate Professor of Pediatrics, University of Pennsylvania

Stephan A Grupp, MD, PhD is a member of the following medical societies: American Association for Cancer Research, American Society for Blood and Marrow Transplantation, American Society of Hematology, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine

Disclosure: Nothing to disclose.

Steven K Bergstrom, MD  Assistant to the Chairman, Department of Pediatrics, Division of Hematology-Oncology, Kaiser Permanente Medical Center of Oakland

Steven K Bergstrom, MD is a member of the following medical societies: Alpha Omega Alpha, American Society of Clinical Oncology, American Society of Hematology, American Society of Pediatric Hematology/Oncology, Children's Oncology Group, and International Society for Experimental Hematology

Disclosure: Nothing to disclose.

Helen SL Chan, MBBS, FRCP(C), FAAP  Senior Scientist, Research Institute; Professor, Division of Hematology/Oncology, Department of Pediatrics, The Hospital for Sick Children, University of Toronto, Canada

Helen SL Chan, MBBS, FRCP(C), FAAP is a member of the following medical societies: American Academy of Pediatrics, American Association for Cancer Research, American Society of Hematology, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

Chief Editor

Max J Coppes, MD, PhD, MBA  Senior Vice President, Children's National Medical Center (Center for Cancer and Blood Disorders); Director, Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center; Professor of Medicine, Oncology, and Pediatrics, Georgetown University

Max J Coppes, MD, PhD, MBA is a member of the following medical societies: American Association for Cancer Research, American Society of Pediatric Hematology/Oncology, and Society for Pediatric Research

Disclosure: Nothing to disclose.

References

  1. Ang JP, Heath JA, Donath S, Khurana S, Auldist A. Treatment outcomes for hepatoblastoma: an institution's experience over two decades. Pediatr Surg Int. Feb 2007;23(2):103-9. [Medline].

  2. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer. Jan 2004;42(1):74-83. [Medline].

  3. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant. Oct 2005;9(5):557-65. [Medline].

  4. Czauderna P, Mackinlay G, Perilongo G, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. Jun 15 2002;20(12):2798-804. [Medline].

  5. Hirschman BA, Pollock BH, Tomlinson GE. The spectrum of APC mutations in children with hepatoblastoma from familial adenomatous polyposis kindreds. J Pediatr. Aug 2005;147(2):263-6. [Medline].

  6. Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: implications for diagnosis and screening. Pediatr Blood Cancer. Nov 2006;47(6):851-4. [Medline].

  7. Harvey J, Clark S, Hyer W, Hadzic N, Tomlinson I, Hinds R. Germline APC mutations are not commonly seen in children with sporadic hepatoblastoma. J Pediatr Gastroenterol Nutr. Nov 2008;47(5):675-7. [Medline].

  8. Anna CH, Sills RC, Foley JF, Stockton PS, Ton TV, Devereux TR. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam. Cancer Res. Jun 1 2000;60(11):2864-8. [Medline].

  9. Koch A, Waha A, Hartmann W, et al. Elevated expression of Wnt antagonists is a common event in hepatoblastomas. Clin Cancer Res. Jun 15 2005;11(12):4295-304. [Medline].

  10. Tan X, Apte U, Micsenyi A, et al. Epidermal growth factor receptor: a novel target of the Wnt/beta-catenin pathway in liver. Gastroenterology. Jul 2005;129(1):285-302. [Medline].

  11. Wirths O, Waha A, Weggen S, et al. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors. Lab Invest. Mar 2003;83(3):429-34. [Medline].

  12. Miao J, Kusafuka T, Udatsu Y, Okada A. Sequence variants of the Axin gene in hepatoblastoma. Hepatol Res. Feb 2003;25(2):174-179. [Medline].

  13. Taniguchi K, Roberts LR, Aderca IN, et al. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas. Oncogene. Jul 18 2002;21(31):4863-71. [Medline].

  14. Kuroda T, Rabkin SD, Martuza RL. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector. Cancer Res. Oct 15 2006;66(20):10127-35. [Medline].

  15. Arsic D, Beasley SW, Sullivan MJ. Switched-on Sonic hedgehog: a gene whose activity extends beyond fetal development - to oncogenesis. J Paediatr Child Health. Jun 2007;43(6):421-3. [Medline].

  16. Eichenmuller M, Gruner I, Hagl B, et al. Blocking the hedgehog pathway inhibits hepatoblastoma growth. Hepatology. Feb 2009;49(2):482-90. [Medline].

  17. Lopez-Terrada D, Gunaratne PH, Adesina AM, et al. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors. Hum Pathol. Jun 2009;40(6):783-94. [Medline].

  18. Ruck P, Xiao JC. Stem-like cells in hepatoblastoma. Med Pediatr Oncol. Nov 2002;39(5):504-7. [Medline].

  19. Tanimura M, Matsui I, Abe J, et al. Increased risk of hepatoblastoma among immature children with a lower birth weight. Cancer Res. Jul 15 1998;58(14):3032-5. [Medline].

  20. Ortega JA, Douglass EC, Feusner JH, et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. J Clin Oncol. Jul 2000;18(14):2665-75. [Medline].

  21. Aronson DC, Schnater JM, Staalman CR, et al. Predictive value of the pretreatment extent of disease system in hepatoblastoma: results from the International Society of Pediatric Oncology Liver Tumor Study Group SIOPEL-1 study. J Clin Oncol. Feb 20 2005;23(6):1245-52. [Medline].

  22. Feusner J, Plaschkes J. Hepatoblastoma and low birth weight: a trend or chance observation?. Med Pediatr Oncol. Nov 2002;39(5):508-9. [Medline].

  23. Oue T, Kubota A, Okuyama H, et al. Hepatoblastoma in children of extremely low birth weight: a report from a single perinatal center. J Pediatr Surg. Jan 2003;38(1):134-7; discussion 134-7. [Medline].

  24. Ucar C, Caliskan U, Toy H. Hepatoblastoma in a child with neurofibromatosis type I. Pediatr Blood Cancer. Nov 10 2005;[Medline].

  25. Toxicology and Carcinogenesis Studies of Bromochloroacetic Acid (CAS No. 5589-96-8) in F344/N Rats and B6C3F1 Mice (Drinking Water Studies). Natl Toxicol Program Tech Rep Ser. Feb 2009;1-270. [Medline].

  26. Fuchs J, Rydzynski J, Von Schweinitz D, et al. Pretreatment prognostic factors and treatment results in children with hepatoblastoma: a report from the German Cooperative Pediatric Liver Tumor Study HB 94. Cancer. Jul 1 2002;95(1):172-82. [Medline].

  27. Figarola MS, McQuiston SA, Wilson F, Powell R. Recurrent hepatoblastoma with localization by PET-CT. Pediatr Radiol. Dec 2005;35(12):1254-8. [Medline].

  28. Rowland JM. Hepatoblastoma: assessment of criteria for histologic classification. Med Pediatr Oncol. Nov 2002;39(5):478-83. [Medline].

  29. von Schweinitz D, Hecker H, Schmidt-von-Arndt G, Harms D. Prognostic factors and staging systems in childhood hepatoblastoma. Int J Cancer. Dec 19 1997;74(6):593-9. [Medline].

  30. Douglass EC, Reynolds M, Finegold M, Cantor AB, Glicksman A. Cisplatin, vincristine, and fluorouracil therapy for hepatoblastoma: a Pediatric Oncology Group study. J Clin Oncol. Jan 1993;11(1):96-9. [Medline].

  31. Casanova M, Massimino M, Ferrari A, et al. Etoposide, cisplatin, epirubicin chemotherapy in the treatment of pediatric liver tumors. Pediatr Hematol Oncol. Apr-May 2005;22(3):189-98. [Medline].

  32. [Best Evidence] Perilongo G, Maibach R, Shafford E, et al. Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma. N Engl J Med. Oct 22 2009;361(17):1662-70. [Medline].

  33. McCrudden KW, Hopkins B, Frischer J, et al. Anti-VEGF antibody in experimental hepatoblastoma: suppression of tumor growth and altered angiogenesis. J Pediatr Surg. Mar 2003;38(3):308-14; discussion 308-14. [Medline].

  34. Warmann S, Gohring G, Teichmann B, Geerlings H, Fuchs J. MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro. J Pediatr Surg. Nov 2002;37(11):1579-84. [Medline].

  35. Warmann S, Hunger M, Teichmann B, Flemming P, Gratz KF, Fuchs J. The role of the MDR1 gene in the development of multidrug resistance in human hepatoblastoma: clinical course and in vivo model. Cancer. Oct 15 2002;95(8):1795-801. [Medline].

  36. Rana AN, Qidwai A, Pritchard J, Ashraf MS. Successful treatment of multifocal unresectable hepatoblastoma with chemotherapy only. Pediatr Hematol Oncol. Mar 2006;23(2):153-8. [Medline].

  37. Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. Feb 1 2009;27(4):550-6. [Medline].

  38. Levy CF, Oo KZ, Fireman F, et al. Reversible posterior leukoencephalopathy syndrome in a child treated with bevacizumab. Pediatr Blood Cancer. May 2009;52(5):669-71. [Medline].

  39. Katzenstein HM, London WB, Douglass EC, et al. Treatment of unresectable and metastatic hepatoblastoma: a pediatric oncology group phase II study. J Clin Oncol. Aug 15 2002;20(16):3438-44. [Medline].

  40. Katzenstein HM, Rigsby C, Shaw PH, Mitchell TL, Haut PR, Kletzel M. Novel therapeutic approaches in the treatment of children with hepatoblastoma. J Pediatr Hematol Oncol. Dec 2002;24(9):751-5. [Medline].

  41. Fuchs J, Rydzynski J, Hecker H, et al. The influence of preoperative chemotherapy and surgical technique in the treatment of hepatoblastoma--a report from the German Cooperative Liver Tumour Studies HB 89 and HB 94. Eur J Pediatr Surg. Aug 2002;12(4):255-61. [Medline].

  42. Finegold MJ. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med Pediatr Oncol. Nov 2002;39(5):484-6. [Medline].

  43. Adesina AM, Lopez-Terrada D, Wong KK, et al. Gene expression profiling reveals signatures characterizing histologic subtypes of hepatoblastoma and global deregulation in cell growth and survival pathways. Hum Pathol. Jun 2009;40(6):843-53. [Medline].

  44. Aihara R, Ohno T, Mochiki E, et al. Gastrointestinal stromal tumor of the lesser omentum in a young adult patient with a history of hepatoblastoma: Report of a case. Surg Today. 2009;39(4):349-52. [Medline].

  45. Beaunoyer M, Vanatta JM, Ogihara M, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant. Sep 2007;11(6):655-60. [Medline].

  46. Blaker H, Hofmann WJ, Rieker RJ, et al. Beta-catenin accumulation and mutation of the CTNNB1 gene in hepatoblastoma. Genes Chromosomes Cancer. Aug 1999;25(4):399-402. [Medline].

  47. Borger JA, Barbosa JL, Lehan CA. Chemotherapy combined with surgery in successful treatment of hepatoblastoma. J Fla Med Assoc. Dec 1989;76(12):1023-6. [Medline].

  48. Cairo S, Armengol C, De Reynies A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell. Dec 9 2008;14(6):471-84. [Medline].

  49. Cohen MM Jr. Beckwith-Wiedemann syndrome: historical, clinicopathological, and etiopathogenetic perspectives. Pediatr Dev Pathol. May-Jun 2005;8(3):287-304. [Medline].

  50. Conran RM, Hitchcock CL, Waclawiw MA, Stocker JT, Ishak KG. Hepatoblastoma: the prognostic significance of histologic type. Pediatr Pathol. Mar-Apr 1992;12(2):167-83. [Medline].

  51. [Guideline] Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer. May 2005;41(7):1031-6. [Medline].

  52. Czauderna P, Zbrzezniak G, Narozanski W, Korzon M, Wyszomirska M, Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer. Jun 2006;46(7):825-8. [Medline].

  53. D'Antiga L, Vallortigara F, Cillo U, et al. Features predicting unresectability in hepatoblastoma. Cancer. Sep 1 2007;110(5):1050-8. [Medline].

  54. Ehrlich PF, Greenberg ML, Filler RM. Improved long-term survival with preoperative chemotherapy for hepatoblastoma. J Pediatr Surg. Jul 1997;32(7):999-1002; discussion 1002-3. [Medline].

  55. Faraj W, Dar F, Marangoni G, et al. Liver transplantation for hepatoblastoma. Liver Transpl. Nov 2008;14(11):1614-9. [Medline].

  56. Feusner J, Buckley J, Robison L, et al. Prematurity and hepatoblastoma: more than just an association?. J Pediatr. Oct 1998;133(4):585-6. [Medline].

  57. Filler RM, Ehrlich PF, Greenberg ML, Babyn PS. Preoperative chemotherapy in hepatoblastoma. Surgery. Oct 1991;110(4):591-6; discussion 596-7. [Medline].

  58. Finegold MJ. Chemotherapy for suspected hepatoblastoma without efforts at surgical resection is a bad practice. Med Pediatr Oncol. Nov 2002;39(5):484-6. [Medline].

  59. Gutweiler JR, Yu DC, Kim HB, et al. Hepatoblastoma presenting with focal nodular hyperplasia after treatment of neuroblastoma. J Pediatr Surg. Dec 2008;43(12):2297-300. [Medline].

  60. Herzog CE, Andrassy RJ, Eftekhari F. Childhood cancers: hepatoblastoma. Oncologist. 2000;5(6):445-53. [Medline].

  61. Horton JD, Lee S, Brown SR, Bader J, Meier DE. Survival trends in children with hepatoblastoma. Pediatr Surg Int. May 2009;25(5):407-12. [Medline].

  62. Kasahara M, Ueda M, Haga H, et al. Living-donor liver transplantation for hepatoblastoma. Am J Transplant. Sep 2005;5(9):2229-35. [Medline].

  63. King SJ, Babyn PS, Greenberg ML, Phillips MJ, Filler RM. Value of CT in determining the resectability of hepatoblastoma before and after chemotherapy. AJR Am J Roentgenol. Apr 1993;160(4):793-8. [Medline].

  64. Li FP, Thurber WA, Seddon J, Holmes GE. Hepatoblastoma in families with polyposis coli. JAMA. May 8 1987;257(18):2475-7. [Medline].

  65. Lopez-Terrada D. Integrating the diagnosis of childhood malignancies. Adv Exp Med Biol. 2006;587:121-37. [Medline].

  66. Mejia A, Langnas AN, Shaw BW, Torres C, Sudan DL. Living and deceased donor liver transplantation for unresectable hepatoblastoma at a single center. Clin Transplant. Dec 2005;19(6):721-5. [Medline].

  67. Meyers RL, Katzenstein HM, Malogolowkin MH. Predictive value of staging systems in hepatoblastoma. J Clin Oncol. Feb 20 2007;25(6):737. [Medline].

  68. Mody RJ, Pohlen JA, Malde S, Strouse PJ, Shulkin BL. FDG PET for the study of primary hepatic malignancies in children. Pediatr Blood Cancer. Jul 2006;47(1):51-5. [Medline].

  69. Molmenti EP, Wilkinson K, Molmenti H, et al. Treatment of unresectable hepatoblastoma with liver transplantation in the pediatric population. Am J Transplant. Jul 2002;2(6):535-8. [Medline].

  70. Otte JB, de Ville de Goyet J. The contribution of transplantation to the treatment of liver tumors in children. Semin Pediatr Surg. Nov 2005;14(4):233-8. [Medline].

  71. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant. Oct 2005;9(5):557-65. [Medline].

  72. Pollock BH, Jenson HB, Leach CT, et al. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. May 14 2003;289(18):2393-9. [Medline].

  73. Pritchard J, Brown J, Shafford E, et al. Cisplatin, doxorubicin, and delayed surgery for childhood hepatoblastoma: a successful approach--results of the first prospective study of the International Society of Pediatric Oncology. J Clin Oncol. Nov 15 2000;18(22):3819-28. [Medline].

  74. Quinn JJ, Altman AJ, Robinson HT, Cooke RW, Hight DW, Foster JH. Adriamycin and cisplatin for hepatoblastoma. Cancer. Oct 15 1985;56(8):1926-9. [Medline].

  75. Raney B. Hepatoblastoma in children: a review. J Pediatr Hematol Oncol. Sep-Oct 1997;19(5):418-22. [Medline].

  76. Ranganathan S, Tan X, Monga SP. beta-Catenin and met deregulation in childhood Hepatoblastomas. Pediatr Dev Pathol. Jul-Aug 2005;8(4):435-47. [Medline].

  77. Reynolds M, Douglass EC, Finegold M, Cantor A, Glicksman A. Chemotherapy can convert unresectable hepatoblastoma. J Pediatr Surg. Aug 1992;27(8):1080-3; discussion 1083-4. [Medline].

  78. Richter A, Grabhorn E, Schulz A, Schaefer HJ, Burdelski M, Ganschow R. Hepatoblastoma in a child with progressive familial intrahepatic cholestasis. Pediatr Transplant. Dec 2005;9(6):805-8. [Medline].

  79. Ross JA, Gurney JG. Hepatoblastoma incidence in the United States from 1973 to 1992. Med Pediatr Oncol. Mar 1998;30(3):141-2. [Medline].

  80. Sallam A, Paes B, Bourgeois J. Neonatal hepatoblastoma: two cases posing a diagnostic dilemma, with a review of the literature. Am J Perinatol. Nov 2005;22(8):413-9. [Medline].

  81. Srinivasan P, McCall J, Pritchard J, et al. Orthotopic liver transplantation for unresectable hepatoblastoma. Transplantation. Sep 15 2002;74(5):652-5. [Medline].

  82. [Guideline] Tan TY, Amor DJ. Tumour surveillance in Beckwith-Wiedemann syndrome and hemihyperplasia: a critical review of the evidence and suggested guidelines for local practice. J Paediatr Child Health. Sep 2006;42(9):486-90. [Medline].

  83. Tomizawa M, Saisho H. Signaling pathway of insulin-like growth factor-II as a target of molecular therapy for hepatoblastoma. World J Gastroenterol. Oct 28 2006;12(40):6531-5. [Medline].

  84. Tomlinson GE, Douglass EC, Pollock BH, Finegold MJ, Schneider NR. Cytogenetic evaluation of a large series of hepatoblastomas: numerical abnormalities with recurring aberrations involving 1q12-q21. Genes Chromosomes Cancer. Oct 2005;44(2):177-84. [Medline].

  85. Trobaugh-Lotrario AD, Tomlinson GE, Finegold MJ, Gore L, Feusner JH. Small cell undifferentiated variant of hepatoblastoma: adverse clinical and molecular features similar to rhabdoid tumors. Pediatr Blood Cancer. Mar 2009;52(3):328-34. [Medline].

  86. Tsuchida Y, Ikeda H, Suzuki N, et al. A case of well-differentiated, fetal-type hepatoblastoma with very low serum alpha-fetoprotein. J Pediatr Surg. Dec 1999;34(12):1762-4. [Medline].

  87. Vogl TJ, Scheller A, Jakob U, Zangos S, Ahmed M, Nabil M. Transarterial chemoembolization in the treatment of hepatoblastoma in children. Eur Radiol. Jun 2006;16(6):1393-6. [Medline].

  88. Wang JD, Chang TK, Chen HC, et al. Pediatric liver tumors: initial presentation, image finding and outcome. Pediatr Int. Aug 2007;49(4):491-6. [Medline].

  89. Warmann SW, Frank H, Heitmann H, et al. Bcl-2 Gene Silencing in Pediatric Epithelial Liver Tumors. J Surg Res. Jan 2008;144(1):43-48. [Medline].

  90. Warmann SW, Heitmann H, Teichmann B, et al. Effects of P-glycoprotein modulation on the chemotherapy of xenotransplanted human hepatoblastoma. Pediatr Hematol Oncol. Jul-Aug 2005;22(5):373-86. [Medline].

  91. Zimmermann A. The emerging family of hepatoblastoma tumours: from ontogenesis to oncogenesis. Eur J Cancer. Jul 2005;41(11):1503-14. [Medline].

 
Previous
Next
 
Clear cell hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Embryonal hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Fetal components of hepatoblastoma. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
Hepatoblastoma. Normal liver tissue. Hematoxylin and eosin stain. Image courtesy of Denise Malicki, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.